by Truveta Research | Nov 10, 2023 | Research, Research Insights
Lecanemab received accelerated FDA approval in January 2023 and full FDA approval in July 2023. A potential side effect of the drug is brain swelling and/or small hemorrhages and is most common for people with the APOE ε4 genetic variant, therefore rates of APOE e4...
by Truveta Research | Nov 2, 2023 | Research, Research Insights
Adalimumab (Humira) and etanercept (Enbrel) are high-cost specialty medications used to treat a variety of autoimmune diseases. Medication adherence is often influenced by social drivers of health, so we aimed to measure adherence using the proportion of days covered...
by Truveta staff | Oct 24, 2023 | Research
Each year, approximately 900,000 patients in the United States are affected by PE, a blood clot causing a blockage in one or more pulmonary arteries in the lungs and a leading cause of in-hospital death in the U.S. Acute pulmonary embolism (PE) is the third-leading...
by Truveta Research | Oct 17, 2023 | Research, Research Insights
Social drivers of health (SDOH), such as increased financial struggles and decreased social support, have been shown to be correlated with decreased medication adherence. In this study, we saw an increased rate of medication adherence for those with individual incomes...
by Truveta staff | Oct 10, 2023 | Research, Research Insights
The aim of this analysis was to compare different prescription trends post-venous stenting and set the foundation for future research. We identified a disparity showing that certain populations are less likely to receive prescriptions for medications within 30 days...
by Truveta Research | Oct 5, 2023 | Research, Research Insights
Annually, over 125,000 deaths are associated with poor medication adherence. The proportion of days covered (PDC) is a common method to measure adherence. When controlling for age, sex, race, and ethnicity, we found similar rates of first year medication adherence for...
